Evommune, Inc. (EVMN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Evommune, Inc. stock (EVMN) is currently trading at $23.16. Evommune, Inc. PS ratio (Price-to-Sales) is 56.57. Analyst consensus price target for EVMN is $51.00. WallStSmart rates EVMN as Sell.
- EVMN PE ratio analysis and historical PE chart
- EVMN PS ratio (Price-to-Sales) history and trend
- EVMN intrinsic value — DCF, Graham Number, EPV models
- EVMN stock price prediction 2025 2026 2027 2028 2029 2030
- EVMN fair value vs current price
- EVMN insider transactions and insider buying
- Is EVMN undervalued or overvalued?
- Evommune, Inc. financial analysis — revenue, earnings, cash flow
- EVMN Piotroski F-Score and Altman Z-Score
- EVMN analyst price target and Smart Rating
Evommune, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Evommune, Inc. (EVMN) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Evommune, Inc. (EVMN) Key Strengths (1)
91.03% of shares held by major funds and institutions
Supporting Valuation Data
Evommune, Inc. (EVMN) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 56.6x annual revenue
Premium pricing at 4.1x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Evommune, Inc. (EVMN) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (56.57), Price/Book (4.09) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -54.40%, Operating Margin at -624.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -54.40% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EVMN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EVMN's Price-to-Sales ratio of 56.57x sits near its historical average of 59.64x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 12% below its historical high of 64.58x set in Feb 2026, and 6% above its historical low of 53.32x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~64.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Evommune, Inc. (EVMN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Evommune, Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Spending 157% of revenue (20M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -17M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Evommune, Inc..
Bottom Line
Evommune, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:11:40 AM
About Evommune, Inc.(EVMN)
NYSE
HEALTHCARE
BIOTECHNOLOGY
USA
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for the treatment of immunological disorders. With a robust pipeline designed to tackle significant unmet medical needs, Evommune leverages advanced research and technology to enhance immune response and patient outcomes. The company's dedication to scientific rigor and strategic partnerships supports its ambition to become a leader in the rapidly evolving field of immunotherapy. As Evommune progresses through clinical trials, it aims to deliver transformative solutions that could redefine care standards in immunology and provide renewed hope for patients.